PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
35346284-12	2022	Anemonin inhibited DSS-induced colon tissue inflammation as the release of IL-1beta, TNF-alpha, and IL-6 was significantly suppressed.	anemonin	0-8	interleukin 1 alpha	Mus musculus	75-83
35346284-12	2022	Anemonin inhibited DSS-induced colon tissue inflammation as the release of IL-1beta, TNF-alpha, and IL-6 was significantly suppressed.	anemonin	0-8	tumor necrosis factor	Mus musculus	85-94
35346284-12	2022	Anemonin inhibited DSS-induced colon tissue inflammation as the release of IL-1beta, TNF-alpha, and IL-6 was significantly suppressed.	anemonin	0-8	interleukin 6	Mus musculus	100-104
35346284-17	2022	Adeno-associated virus delivery of the PRKCQ vector significantly reversed the protective effects of anemonin on the mouse colon.	anemonin	101-109	protein kinase C theta	Homo sapiens	39-44
35346284-19	2022	The anti-inflammatory effects of anemonin may be mediated through targeting PKC-theta.	anemonin	33-41	protein kinase C, theta	Mus musculus	76-85
28643466-11	2017	ANE is a potent protective molecule for OA; it delays OA progression by suppressing ECM loss and chondrocyte hypertrophy partially by suppressing IL-1beta/NF-kappaB pathway activation.	anemonin	0-3	interleukin 1 beta	Mus musculus	146-154
31344701-0	2019	Regulation of iRhom-2/Tumor Necrosis Factor-alpha Converting Enzyme Pathway and Oxidative Stress Protects the Renal Injury with Anemonin in Streptozotocin-Induced Diabetic Nephropathy Neonatal Rat Model.	anemonin	128-136	tumor necrosis factor	Rattus norvegicus	22-49
31344701-4	2019	Effect of anemonin was estimated by determining the blood glucose, markers of nephropathy, and mediators of inflammation in the serum and activity of tumor necrosis factor-alpha (TNF-alpha)converting enzyme (TACE) in the kidney tissue of DN rats.	anemonin	10-18	tumor necrosis factor	Rattus norvegicus	150-177
31344701-4	2019	Effect of anemonin was estimated by determining the blood glucose, markers of nephropathy, and mediators of inflammation in the serum and activity of tumor necrosis factor-alpha (TNF-alpha)converting enzyme (TACE) in the kidney tissue of DN rats.	anemonin	10-18	ADAM metallopeptidase domain 17	Rattus norvegicus	179-206
31344701-4	2019	Effect of anemonin was estimated by determining the blood glucose, markers of nephropathy, and mediators of inflammation in the serum and activity of tumor necrosis factor-alpha (TNF-alpha)converting enzyme (TACE) in the kidney tissue of DN rats.	anemonin	10-18	ADAM metallopeptidase domain 17	Rattus norvegicus	208-212
31344701-9	2019	There was a reduction in the level of cytokines in the serum, and production of ROS and activity of TACE were reduced in the kidney tissue of the anemonin-treated group than in the DN group.	anemonin	146-154	ADAM metallopeptidase domain 17	Rattus norvegicus	100-104
31344701-10	2019	Expression of iRhom-2, TACE, TNF-alpha, and inducible nitric oxide synthase protein and histopathology of kidney tissue were attenuated in the anemonin-treated group in DN rats.	anemonin	143-151	ADAM metallopeptidase domain 17	Rattus norvegicus	23-27
31344701-10	2019	Expression of iRhom-2, TACE, TNF-alpha, and inducible nitric oxide synthase protein and histopathology of kidney tissue were attenuated in the anemonin-treated group in DN rats.	anemonin	143-151	tumor necrosis factor	Rattus norvegicus	29-38
31344701-10	2019	Expression of iRhom-2, TACE, TNF-alpha, and inducible nitric oxide synthase protein and histopathology of kidney tissue were attenuated in the anemonin-treated group in DN rats.	anemonin	143-151	nitric oxide synthase 2	Rattus norvegicus	44-75
31344701-11	2019	In conclusion, data of study reveal that treatment with anemonin ameliorates progression of renal injury by regulating TACE/iRhom-2 signaling pathway.	anemonin	56-64	ADAM metallopeptidase domain 17	Rattus norvegicus	119-123
28643466-10	2017	ANE treatment also attenuated proteoglycan loss in human cartilage explants treated with IL-1beta ex vivo.	anemonin	0-3	interleukin 1 beta	Homo sapiens	89-97
27189428-10	2016	Supplementation with anemonin also increased TGF-beta1 mRNA and protein expression, Smad4 and Smad7 mRNA expressions, and epidermal growth factor and epidermal growth factor receptor (EGFR) mRNA expression in the jejunal mucosa.	anemonin	21-29	transforming growth factor beta 1	Sus scrofa	45-54
27189428-10	2016	Supplementation with anemonin also increased TGF-beta1 mRNA and protein expression, Smad4 and Smad7 mRNA expressions, and epidermal growth factor and epidermal growth factor receptor (EGFR) mRNA expression in the jejunal mucosa.	anemonin	21-29	SMAD family member 4	Sus scrofa	84-89
27189428-10	2016	Supplementation with anemonin also increased TGF-beta1 mRNA and protein expression, Smad4 and Smad7 mRNA expressions, and epidermal growth factor and epidermal growth factor receptor (EGFR) mRNA expression in the jejunal mucosa.	anemonin	21-29	SMAD family member 7	Sus scrofa	94-99
27189428-10	2016	Supplementation with anemonin also increased TGF-beta1 mRNA and protein expression, Smad4 and Smad7 mRNA expressions, and epidermal growth factor and epidermal growth factor receptor (EGFR) mRNA expression in the jejunal mucosa.	anemonin	21-29	epidermal growth factor receptor	Sus scrofa	150-182
27189428-10	2016	Supplementation with anemonin also increased TGF-beta1 mRNA and protein expression, Smad4 and Smad7 mRNA expressions, and epidermal growth factor and epidermal growth factor receptor (EGFR) mRNA expression in the jejunal mucosa.	anemonin	21-29	epidermal growth factor receptor	Sus scrofa	184-188
17766092-0	2008	Anemonin is a natural bioactive compound that can regulate tyrosinase-related proteins and mRNA in human melanocytes.	anemonin	0-8	tyrosinase	Homo sapiens	59-69
17766092-4	2008	METHODS: The natural compound, anemonin, was isolated from Clematis crassifolia Benth and was used to inhibit cellular TYR activity; it was found to have a low cytotoxicity (cell viability > 80%) in human melanocytes.	anemonin	31-39	tyrosinase	Homo sapiens	119-122
17766092-9	2008	Anemonin inhibits melanin synthesis by inhibiting the transcription of the genes encoding MITF, TYR, TRP1, and TRP2.	anemonin	0-8	melanocyte inducing transcription factor	Homo sapiens	90-94
17766092-9	2008	Anemonin inhibits melanin synthesis by inhibiting the transcription of the genes encoding MITF, TYR, TRP1, and TRP2.	anemonin	0-8	tyrosinase	Homo sapiens	96-99
17766092-9	2008	Anemonin inhibits melanin synthesis by inhibiting the transcription of the genes encoding MITF, TYR, TRP1, and TRP2.	anemonin	0-8	tyrosinase related protein 1	Homo sapiens	101-105
17766092-9	2008	Anemonin inhibits melanin synthesis by inhibiting the transcription of the genes encoding MITF, TYR, TRP1, and TRP2.	anemonin	0-8	dopachrome tautomerase	Homo sapiens	111-115
19472295-3	2009	The results revealed that PD, anemonin, berberine, and esculetin inhibited the production of NO; PD, anemonin, and esculetin inhibited the secretion of ET-1; PD, anemoside B(4), berberine, jatrorrhizine, and aesculin downregulated TNF-alpha expression; PD, anemoside B(4), berberine, and palmatine decreased the content of IL-1 alpha.	anemonin	101-109	endothelin 1	Rattus norvegicus	152-156
18281171-9	2008	These results indicated that the potential anti-inflammatory effect of anemonin, the naturally occurring selective iNOS inhibitor, may provide a rationale for the medical use of Clematis crassifolia.	anemonin	71-79	nitric oxide synthase 2, inducible	Mus musculus	115-119